PD

Peter DiLaura

President and CEO at Initial Therapeutics

San Francisco, California

Invests in

Stages:

  • Min Investment:

    $10,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Education

Work Experience

  • President and CEO

    2024

  • Strategic Advisor

    2024

  • Chief Business and Strategy Officer

    2020 - 2024

    Member of the Executive Team, responsible for all elements of company operations and strategy, including financing, corporate development and partnering, financial operations, program and portfolio management, legal, and HR. - Led financing efforts, including $265M Series B financing - Led corporate development efforts, including principal sourcing and negotiation of multi-indication discovery, development, and commercialization collaboration with Regeneron, with $75M upfront, $45M in early milestones, and 50/50 cost and profit sharing structure - Built and managed Finance, Legal, HR, and Program Management functions

  • Member Board of Directors

    2020

2018 - 2020

  • Entrepreneur In Residence

    2018 - 2020

    Led and supported incubation efforts for multiple early company concepts.

  • Strategic Advisor

    2017 - 2019

2017 - 2017

  • Advisor

    2017 - 2017

2010 - 2016

  • President & CEO

    2010 - 2016

    CEO and Director of Second Genome, a South San Francisco biotechnology company developing novel drugs from microbiome science. Led the company from an early team of founders to 30 employees.

2001 - 2010

  • Senior Vice President

    2001 - 2010

    Commercial roles with increasing responsibility at Ingenuity Systems, a Bay Area systems biology company.

1999 - 2001

  • Vice President, Business Development

    1999 - 2001

    Responsible for corporate strategy, business development, and marketing activities for publicly traded life sciences e-commerce pioneer.

  • Consultant

    1995 - 1999

    Strategic consulting to clients in the pharmaceutical, biotech, medical device and diagnostic industries, focused on opportunity assessment, merger and acquisition advisory, and strategic planning.